vascular endothelial growth factor (VEGF) release (Zhang et al, 1994; Ollivier et al, 1998) . In non-small cell lung carcinoma, the correlation was demonstrated between TF expression and angiogenic indicators exemplified by microvessel density (MVD) and VEGF expression, and co-localization of TF and VEGF was shown in both lung cancer and breast cancer cells (Koomägi and Volm, 1998; Shoji et al, 1998) . TF expression in melanoma cells induced metastasis independent of the blood coagulation pathway (Bromberg et al, 1995) , and, to the contrary, inhibition of TF function in human melanoma cells led to reduced haematogenous metastasis (Mueller et al, 1992) . These findings suggest that TF is deeply involved in tumour progression both as an initiator of the coagulation pathway and as a mediator of signal transduction.
In the present study, we assessed plasma and tissue TF expression in breast cancer patients and showed its clinical significance, especially the prognostic value of TF.
PATIENTS AND METHODS

Patients
Two hundred and thirteen primary breast cancer patients, 24 recurrent breast cancer patients, and 18 benign breast disease patients treated at Tokyo Metropolitan Komagome Hospital from 1983-1996 were enrolled in this study. All patients were female. All primary cancer patients had no distant metastases. Patients with liver and renal dysfunction were excluded from this study. Informed consent was obtained from all. The patients' age ranged from 29-85 years, and the average age was 52.3. Clinical stages were determined according to the criteria of the Japanese Breast Cancer Society which is based on the Union Internationale Contre le Cancer (UICC) criteria. All primary patients received either Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration mastectomy or partial mastectomy with axillary lymph-node dissection. Adjuvant treatments were applied according to the following criteria which did not take account of the TF expression levels: polychemotherapy was given for 6 months to patients under the age of 55 with metastasized lymph nodes and hormonal therapy (tamoxifen) was given to oestrogen receptor (OR)-positive patients for more than 2 years. In the study, 173 patients received adjuvant therapy, including 53 chemotherapy, 38 hormonal therapy, and 82 chemo-endocrine therapy. For all patients, postoperative physical examinations were performed at least every 3 months. The median follow-up period of surviving patients was 53 months. Liver, lung, brain and distant lymph-node metastases were diagnosed using computed tomographic scan, and bone metastasis was diagnosed using X-ray and bone scintigraphy. In 24 recurrent cancer patients, major recurrent sites were found in liver (n = 4), lung (n = 1), bone (n = 5), and lymph node (n = 14). All recurrent patients were provided with the following treatments: nine with systemic chemotherapy, four with hormonal therapy, eight with chemo-endocrine therapy, and three with surgical resection. Eighteen benign breast disease patients included nine fibroadenoma, five mastopathy, and four intraductal papilloma.
ELISA
Using plasma from 24 healthy female controls, 18 benign breast disease patients, 43 primary and 24 recurrent breast cancer patients who were treated from 1995-1996, circulating TF concentrations were examined. Venous blood samples were drawn into sterile vacuum tubes with 3.2% sodium citrate at the time of the diagnosis of primary breast cancer or recurrent cancer before treatments. They were centrifuged at 3000 rpm for 10 min and stored at -20°C until use. The TF level in the plasma was determined by enzymelinked immunosorbent assay (ELISA) (Bobrow et al, 1989; Nakamura et al, 1993) . This ELISA system adopted a sandwich method using two anti-TF monoclonal antibodies (mAbs) (HTF-K14, HTF-K180). Ninety six-well plates were coated with HTF-K14 and blocked with bovine serum albumin (BSA, Fraction V, Bayer, Germany). After incubation, HTF-K180 conjugated with horseradish peroxidase (HRP) was added. Then, to amplify the sensitivity, biotinyl-tyramide (Dupont)/H 2 O 2 was added, followed by incubation with HRP-conjugated streptavidin (Amersham). After washing, 2,2′-azino-bis (3-athylbenz-thiazoline-6-sulfonic acid) (Boehringer Mannheim Biochemica)/H 2 O 2 was added as a substrate. The reaction was stopped with 0.01% NaN 3 0.1 mol l -1 citric acid and absorbance at 420 nm was measured with the reference absorbance at 630 nm. Tissue factor was highly purified from human placenta with an anti-tissue factor antibody (HTF-K14) column and used as a standard for tissue factor ELISA. Detection limit of this ELISA was 10 pg ml -1 .
Immunohistochemistry
To assess TF expression, 3-5 µm sections of 213 paraffinembedded breast cancer tissues, containing tissues from all patients whose plasma TF levels were measured, were applied to indirect anti-peroxidase immunohistochemical assay (Dako, CA, USA) using an anti-TF mAb (HTF-K108) (Imamura et al, 1993) . After the inhibition of endogenous peroxidase activity, sections were stained with HTF-K108, followed by reaction with peroxidase-labelled anti-mouse immunoglobulin (Dako, CA, USA).
Peroxidase activity was visualized using 3,3′-diaminobenzidine (Nakalai Tesque, Kyoto, Japan) as substrate. After immunostaining, the sections were counterstained with haematoxylin (Muto Pure Chemicals Co, Ltd, Tokyo, Japan). TF-positive cancer cells (tumour TF) and stromal cells (stromal TF) were separately counted in the most accumulated five areas in a × 200 microscopic field. In each of cancer and stroma, the average of the counts was regarded as TF-positive cell density, which was classified into three groups: -= < 10%, + = 10-50%, ++ = > 50%. The immunohistochemical and pathological assessment was carried out by two pathologists who had no information of clinical conditions and plasma TF levels.
Hormone receptor assay
Oestrogen receptor (OR) and progesterone receptor (PgR) were measured by dextran-coated charcoal (DCC) method using 3 H-17 oestradiol or by EIA method. The cut-off values were determined as 5 fmol mg -1 protein for both hormone receptors.
Statistical analysis
Plasma TF concentration was compared using analysis of variance (ANOVA) and Fisher's protected least-significant difference (PLSD). The chi-square test was carried out for qualitative analysis. The Spearman's correlation coefficient by rank was performed to evaluate the correlation between tissue TF expression and plasma TF concentration. The survival curves were drawn by Kaplan-Meier method, and the difference in prognosis between two groups was analysed by the log-rank test. The Figure 1 Plasma TF concentration in normal controls, benign breast disease patients, and breast cancer patients. Primary and recurrent breast cancer patients had a significantly higher TF concentration than normal controls (P = 0.0014 and 0.0114, respectively). There was no difference between normal controls and benign breast disease patients (P = 0.12) and between primary and recurrent breast cancer patients (P = 0.71). Among recurrent sites, no significant difference was observed in plasma TF concentration (P = 0.68) relative risk for each indicator was evaluated by the multivariate Cox proportional hazards model. P < 0.05 was considered to indicate statistical significance.
RESULTS
ELISA
The median levels of plasma TF concentration in normal female controls, benign breast disease, and primary and recurrent breast cancer patients were 83.85 (25th-75th percentile: 72.40-92.55), 106.1 (94.03-131.3), 111.6 (77.33-155.4), and 120.1 (92.02-145.0) pg ml -1 respectively (Figure 1 ). Statistical analysis demonstrated that primary and recurrent breast cancer patients showed significantly higher plasma TF concentration than normal controls (P = 0.0014 and 0.0114, respectively), whereas there was no difference between normal controls and benign breast disease patients (P = 0.12), and between primary and recurrent breast cancer patients (P = 0.71). In primary cancer patients, plasma TF concentration was not significantly associated with any clinical parameters including clinical stage, tumour size, lymph-node metastasis, hormone receptor status and pathological findings (data not shown). In the case of recurrent cancer patients, although patients with liver metastasis tended to have high plasma TF concentration, there was no statistical difference among patients with different recurrent sites (P = 0.68, Figure 1 ).
Immunohistochemical study
TF expression was observed in tumour cells, fibroblastic cells, monocytic cells, and vascular endothelial cells (Figure 2 ). Among 213 primary breast cancer tissues, tumour TF expression was detected in 193 (90.6%) tissues including 117 + and 76 ++, and stromal TF expression was detected in almost all tissues (210 tissues, 98.6%) (Figure 2 , Table 1 ). Tumour TF expression closely correlated with stromal TF expression (P = 0.0005, Table 1 ). Table  1 shows that both tumour and stromal TF expression were not associated with any clinical parameters, such as clinical stage, hormone-receptor status, lymph-node metastasis, and adjuvant treatments. We assessed the relationship between plasma TF concentration and TF expression in cancer tissues. Plasma TF concentration was significantly associated with staining intensity of TF in cancer tissues. Figure 3 shows that there was a close correlation between plasma TF levels and TF expression, not only in tumour cells but also stromal cells (P = 0.0069 and 0.0003, respectively). Survival analysis revealed that tumour TF-negative patients (n = 20) had a significantly better prognosis than tumour TF-positive patients (n = 193) for overall survival (P = 0.041), although no significant difference was shown for disease-free survival (P = 0.266) (Figure 4) . Moreover, tumour TF expression was proved to be an independent prognostic indicator for overall survival by the multivariate analysis (hazard ratio = 4.275, P = 0.0452, Table 2 ). During the follow-up period, 85 patients underwent recurrence, and recurrent sites are shown in Table 3 . Among tumour TF-negative patients (mean follow-up period = 84 months, range = 1-175 months), no metastases in liver, lung, and brain were observed, whereas 36.7% of tumour TF-positive patients (mean follow-up period = 58 months, range = 7-173 months) underwent metastases in those sites.
DISCUSSION
Plasma TF concentration has been reported to be increased in various disease such as disseminated intravascular coagulation (DIC), ischaemic heart disease, antiphospholipid syndrome, and cancer (Koyama et al, 1994; Takahashi et al, 1994; Wada et al, 1994; Suefuji et al, 1997; Cuadrando et al, 1998; Falciani et al, 1998; Misumi et al, 1998) . We showed that plasma TF concentration was up-regulated in primary and recurrent breast cancer patients. In glioblastoma cells, shedding of TF was shown, suggesting that increased concentration of TF in cancer patients may result from TF emission from tumour cells as well as stromal cells (Bastida et al, 1994) . We demonstrated that there was a significant correlation between plasma TF concentration and tissue TF expression in both tumour and stroma, supporting the view that TF expression in plasma derives from both tumour cells and stromal cells, including macrophages and endothelium, in cancer patients. Previously we showed that plasma TF in female controls was lower than that in male controls and, in this study, we used female controls because all patients were female.
In the immunohistochemical study, we confirmed that TF was widely expressed in both tumour cells and stromal cells, and that tumour TF expression was a predictor of poor prognosis in breast cancer. It was reported that TF expression in tumour cells correlated with grade of malignancy in glioma and pancreatic cancer Hamada et al, 1996) . In addition, numerous studies have clarified the role of TF in metastasis and angiogenesis. In colorectal cancer, TF expression in metastatic liver tumours increased compared with primary tumours (Shigemori et al, 1998) . Our data showed that tumour TF-positive and -negative patients differed in the distribution of recurrent sites. In particular, none of the tumour TF-negative patients had liver metastasis, although this result is preliminary. Liver metastasis is well-known to provide a poor prognosis in breast cancer patients (Yamamoto et al, 1998) . Taken together, although no difference in prognosis was observed for disease-free survival, the difference in metastatic sites between tumour TF-positive and -negative patients might result in the significant difference in prognosis for overall survival. Since the number of tumour TF-negative patients was small, additional studies are needed to confirm our results. However, our data imply the importance of TF expression in breast cancer progression.
Several studies reported that TF was expressed in breast cancer cells, but the expression varied in degree from 37.5-100% among investigators (Callander et al, 1992; Contrino et al, 1996; Vrana et al, 1996) . Our study showed that tumour TF-expression was observed in more than 90% of the breast cancer tissues. Although this discrepancy may result from differences in the sensitivity of antibodies, the preparation method of tissues, the condition of immunohistochemistry, and the criteria of TF-expression levels, our data coincides with recent studies showing that tumour TF-expression was observed in almost all breast cancer tissues (Contrino et al, 1996; Vrana et al, 1996) .
Recently, several new findings on the role of tissue factor came out. The binding of FVIIa to TF induces intracellular calcium ion oscillation, tyrosine phosphorylation, up-regulation of poly-A polymerase mRNA and activation of the MAP kinase pathway, indicating that TF functions not only as a coagulation factor but also as a mediator of intracellular signaling (Rottingen et al, 1995; Masuda et al, 1996; Pendurthi et al, 1997; Poulsen et al, 1998) . TF was reported to be associated with the γ chain homodimer of the IgE receptor type I in monocytes (Masuda et al, 1996) . In addition, TF-FVIIa pathway was demonstrated to enhance urokinase receptor (uPAR) expression in cancer cells, leading to tumour invasion (Taniguchi et al, 1998) . Two-hybrid screening revealed interaction of TF cytoplasmic domain with actin-binding protein 280 (ABP-280), which mediates cell adhesion and migration (Ott et al, 1998) . These observations suggest that TF might modify the phenotype of cells into an invasive one by activation of certain signal transduction pathways. In fact, Chinese hamster ovary (CHO) cells transfected with TF were reported to acquire metastatic potential in SCID mice . This phenotypic change may contribute to a poor prognosis in TFpositive patients. In conclusion, this study demonstrated the association between the concentration of plasma TF and TF-expression in cancer tissues, and the significance of tumour TF-expression as an independent prognostic indicator for overall survival. It may contribute to a poor prognosis that TF promotes cancer invasion and metastasis both through activation of the blood coagulation cascade and through activation of certain intracellular signaling in TFexpressing cells. A clear identification of the extra-and intracellular function of TF will add greatly to the understanding of the mechanism of cancer invasion and metastasis.
